EFTA00447981Set 9
2017-03-243p1,031w
revascularization). Key secondary efficacy endpoints included a
composite of cardiovascular death, MI, or stroke.
Lower LDL, No Effect on Cardiovascular Mortality
The researchers reported that the least-squares mean percentage ... said in a conference press release.
"These data strongly suggest that patients benefit from lowering
LDL cholesterol well below current targets."
Regarding individual outcomes, no observed effect on
cardiovascular mortality
https://www.justice.gov/epstein/files/DataSet%209/EFTA00447981.pdf
EFTA00447987Set 9
2017-03-244p1,054w
revascularization). Key secondary efficacy endpoints included a
composite of cardiovascular death, MI, or stroke.
Lower LDL, No Effect on Cardiovascular Mortality
The researchers reported that the least-squares mean percentage ... said in a conference press release. "These data strongly suggest that patients
benefit from lowering LDL cholesterol well below current targets."
Regarding individual outcomes, no observed effect on cardiovascular mortality
https://www.justice.gov/epstein/files/DataSet%209/EFTA00447987.pdf
EFTA00447984Set 9
2017-03-243p1,043w
revascularization). Key secondary efficacy endpoints included a
composite of cardiovascular death, MI, or stroke.
Lower LDL, No Effect on Cardiovascular Mortality
The researchers reported that the least-squares mean percentage ... said in a conference press release.
-These data strongly suggest that patients benefit from lowering
LDL cholesterol well below current targets."
Regarding individual outcomes, no observed effect on
cardiovascular mortality
https://www.justice.gov/epstein/files/DataSet%209/EFTA00447984.pdf